Casau NC Perspective on HIV infection and aging: emerging research on the horizon. Clin Infect Dis. 2005 Sep 15;41(6):855-63. doi: 10.1086/432797. Epub 2005 Jul 28.
Cohen RA, Seider TR, Navia B HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease? Alzheimers Res Ther. 2015 Apr 6;7(1):37. doi: 10.1186/s13195-015-0123-4. eCollection 2015.
Damirchi A, Tehrani BS, Alamdari KA, Babaei P Influence of aerobic training and detraining on serum BDNF, insulin resistance, and metabolic risk factors in middle-aged men diagnosed with metabolic syndrome. Clin J Sport Med. 2014 Nov;24(6):513-8. doi: 10.1097/JSM.0000000000000082.
Fillipas S, Oldmeadow LB, Bailey MJ, Cherry CL A six-month, supervised, aerobic and resistance exercise program improves self-efficacy in people with human immunodeficiency virus: a randomised controlled trial. Aust J Physiother. 2006;52(3):185-90. doi: 10.1016/s0004-9514(06)70027-7.
Gill AJ, Kolson DL Chronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistence. Curr HIV/AIDS Rep. 2014 Sep;11(3):325-35. doi: 10.1007/s11904-014-0210-3.
Masters MC, Ances BM Role of neuroimaging in HIV-associated neurocognitive disorders. Semin Neurol. 2014 Feb;34(1):89-102. doi: 10.1055/s-0034-1372346. Epub 2014 Apr 8.
Mattson MP Exercise and the brain: a slap on the HAND. J Neurovirol. 2013 Oct;19(5):407-9. doi: 10.1007/s13365-013-0208-4. Epub 2013 Sep 27. No abstract available.
Ortega M, Ances BM Role of HIV in amyloid metabolism. J Neuroimmune Pharmacol. 2014 Sep;9(4):483-91. doi: 10.1007/s11481-014-9546-0. Epub 2014 May 10.
Rao AK, Chou A, Bursley B, Smulofsky J, Jezequel J Systematic review of the effects of exercise on activities of daily living in people with Alzheimer's disease. Am J Occup Ther. 2014 Jan-Feb;68(1):50-6. doi: 10.5014/ajot.2014.009035.
Rodrigues AM, O'Brien N, French DP, Glidewell L, Sniehotta FF The question-behavior effect: genuine effect or spurious phenomenon? A systematic review of randomized controlled trials with meta-analyses. Health Psychol. 2015 Jan;34(1):61-78. doi: 10.1037/hea0000104. Epub 2014 Aug 18.
Rosenfield PL The potential of transdisciplinary research for sustaining and extending linkages between the health and social sciences. Soc Sci Med. 1992 Dec;35(11):1343-57. doi: 10.1016/0277-9536(92)90038-r.
Shah S, Mildvan D HIV and aging. Curr Infect Dis Rep. 2006 May;8(3):241-7. doi: 10.1007/s11908-006-0065-x.
Spudich S, Gonzalez-Scarano F HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med. 2012 Jun;2(6):a007120. doi: 10.1101/cshperspect.a007120.
Spudich S HIV and neurocognitive dysfunction. Curr HIV/AIDS Rep. 2013 Sep;10(3):235-43. doi: 10.1007/s11904-013-0171-y.
Xu J, Ikezu T The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J Neuroimmune Pharmacol. 2009 Jun;4(2):200-12. doi: 10.1007/s11481-008-9136-0. Epub 2008 Nov 19.
Exercise Training to Improve Brain Health in Older HIV+ Individuals
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.